Document Detail

Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers.
MedLine Citation:
PMID:  19178874     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To investigate the pharmacokinetics of L-carnitine (LC) and its analogues, acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) in healthy volunteers after single L-carnitine administration. METHODS: Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma and urine concentrations of L-carnitine, ALC and PLC were detected by HPLC. RESULTS: The maximum plasma concentration (Cmax) and area under the curve (AUC 0-infinity) of L-carnitine was 84.7+/-25.2 micromol x L(-1) x h and 2676.4+/-708.3 micromol x L(-1) x h, respectively. The elimination half-life of L-carnitine and the time required to reach the Cmax (Tmax) was 60.3+/-15.0 and 3.4+/-0.46 h, respectively. The Cmax of ALC (12.9+/-5.5 micromol x L(-1)) and PLC (5.08+/-3.08 micromol x L(-1)) was lower than L-carnitine (P < 0.01), so as the AUC 0-infinity (166.2+/-77.4 and 155.6+/-264.2 micromol x L(-1) x h, respectively, P < 0.01). The half-life of ALC (35.9+/-28.9h) and PLC (25.7+/-30.3 h) was also shorter than L-carnitine (P < 0.01). The 24h accumulated urinary excretion of L-carnitine, ALC and PLC were 613.5+/-161.7, 368.3+/-134.8 and 61.3+/-37.8 micromol, respectively. CONCLUSION: L-carnitine has a greater maximum plasma concentration than ALC and PLC. L-carnitine also has a longer half-life than ALC and PLC. These data may have important implications in the designing of dosing regimens for L-carnitine or its analogues, such as ALC or PLC.
Yu Cao; Yun-xiao Wang; Cheng-juan Liu; Le-xin Wang; Zhi-wu Han; Chun-bo Wang
Related Documents :
12186774 - Hydroxyproline distribution in the plasma of various mammals.
22070634 - Experimental hypothyroidism delays fepsps and disrupts hippocampal long-term potentiati...
11848284 - Tissue distribution of and species differences in deacetylation of n-acetyl-l-cysteine ...
3855234 - Pharmacokinetics of a new antihypertensive pyrrolyl pyridazinamine (mdl-899) in the rat...
19082714 - Involvement of hepatic stimulator substance in experimentally induced fibrosis and cirr...
3440264 - Improved myocardial capillarisation in spontaneously hypertensive rats treated with nif...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2009-02-01
Journal Detail:
Title:  Clinical and investigative medicine. Médecine clinique et experimentale     Volume:  32     ISSN:  1488-2353     ISO Abbreviation:  Clin Invest Med     Publication Date:  2009  
Date Detail:
Created Date:  2009-01-30     Completed Date:  2009-04-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7804071     Medline TA:  Clin Invest Med     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  E13-9     Citation Subset:  IM    
The Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylcarnitine / blood,  pharmacokinetics*
Administration, Oral
Area Under Curve
Carnitine / administration & dosage,  analogs & derivatives*,  blood,  pharmacokinetics*
Chromatography, High Pressure Liquid
Reference Values
Reg. No./Substance:
14992-62-2/Acetylcarnitine; 17298-37-2/propionylcarnitine; 541-15-1/Carnitine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Terazosin treatment suppresses basic fibroblast growth factor expression in the rat ventral prostate...
Next Document:  Serum IgA1 from patients with IgA nephropathy up-regulates integrin-linked kinase synthesis and inhi...